| Biological Sciences | 2021-2025 | 145 | US 24 | 99.87 |
| Medical and Health Sciences | 2021-2025 | 410 | US 140 | 99.91 |
| Oncology | Lifetime | 456 | US 258 | 99.19 |
| Cancer Research | Lifetime | 594 | US 314 | 96.01 |
| Molecular Biology | 2021-2025 | 88 | US 19 | 99.65 |
| Oncology | 2021-2025 | 45 | US 18 | 99.74 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 144 | US 46 | 99.01 |
| Cancer Research | 2021-2025 | 77 | US 31 | 96.48 |
| Immunology | 2021-2025 | 469 | US 170 | 87.01 |
| Pathology and Forensic Medicine | 2021-2025 | 418 | US 139 | 82.77 |
| Hematology | 2021-2025 | 458 | US 210 | 56.38 |
| PARP inhibition in cancer therapy | Lifetime | 49 | US 27 | 99.07 |
| DNA Repair Mechanisms | Lifetime | 188 | US 119 | 98.90 |
| Cancer Genomics and Diagnostics | Lifetime | 468 | US 268 | 99.12 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 188 | US 115 | 98.32 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 727 | US 363 | 98.44 |
| Lung Cancer Treatments and Mutations | Lifetime | 867 | US 401 | 98.28 |
| Cancer therapeutics and mechanisms | Lifetime | 435 | US 235 | 97.72 |
| Cancer Mechanisms and Therapy | Lifetime | 294 | US 136 | 96.94 |
| Advanced Breast Cancer Therapies | Lifetime | 296 | US 139 | 97.58 |
| BRCA gene mutations in cancer | Lifetime | 864 | US 444 | 95.13 |
| DNA Repair Mechanisms | 2021-2025 | 1 | US 1 | 99.83 |
| PARP inhibition in cancer therapy | 2021-2025 | 5 | US 1 | 99.74 |
| Cancer Genomics and Diagnostics | 2021-2025 | 64 | US 35 | 99.39 |
| Cancer-related Molecular Pathways | 2021-2025 | 14 | US 6 | 98.75 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 329 | US 129 | 98.72 |
| Cancer therapeutics and mechanisms | 2021-2025 | 47 | US 21 | 95.75 |
| Advanced Breast Cancer Therapies | 2021-2025 | 139 | US 50 | 97.71 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 790 | US 247 | 95.17 |
| Cell death mechanisms and regulation | 2021-2025 | 40 | US 9 | 90.73 |
| HER2/EGFR in Cancer Research | 2021-2025 | 298 | US 106 | 95.26 |
| BRCA gene mutations in cancer | 2021-2025 | 393 | US 190 | 90.25 |
| interferon and immune responses | 2021-2025 | 463 | US 98 | 87.23 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 149 | US 70 | 85.56 |
| Cancer Treatment and Pharmacology | 2021-2025 | 636 | US 224 | 88.48 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 886 | US 514 | 81.85 |
| Cancer Research and Treatments | 2021-2025 | 961 | US 248 | 78.21 |
| Chromatin Remodeling and Cancer | 2021-2025 | 292 | US 128 | 75.09 |
| Statistical Methods in Clinical Trials | 2021-2025 | 493 | US 213 | 78.66 |
| Occupational and environmental lung diseases | 2021-2025 | 646 | US 148 | 75.33 |
| TGF-β signaling in diseases | 2021-2025 | 124 | US 25 | 69.15 |
| Nuclear Structure and Function | 2021-2025 | 758 | US 265 | 53.46 |
| Mechanisms of cancer metastasis | 2021-2025 | 77 | US 15 | 53.75 |
| Protein Tyrosine Phosphatases | 2021-2025 | 946 | US 281 | 34.55 |